Anzeige
Erschienen in:
01.08.2013 | Original Article
Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
Erschienen in: Pediatric Nephrology | Ausgabe 8/2013
Einloggen, um Zugang zu erhaltenAbstract
Background
mTOR inhibitors (mTORI) have emerged as alternative and additive immunosuppressive agents in pediatric renal transplantation (pRTx). Their immunosuppressive, anti-proliferative, and anti-neoplastic mechanisms have been described to be effective, whereas some side effects are alarming. In particular, growth and pubertal development are of concern. The aim of this study was to look for long-term side effects of mTORI therapy in pRTx.
Patients and methods
The retrospective analysis focused on side effects, growth, and pubertal development under mTORI therapy in 31 children. Eighteen children were routinely monitored for estradiol, testosterone, LH, and FSH levels.
Results
The occurrence of bacterial infections, lymphoceles, myelosuppression, and the course of overall linear growth was comparable with other pediatric renal transplant cohorts. According to the clinical puberty status, all but one patient showed normal age-related development in parallel to normal serum hormone levels. Only one patient experienced cytomegaly virus infection under mTORI, no post-transplant lymphoproliferative disorders (PTLD) occurred.
Conclusions
Long-term mTORI therapy is safe in pRTx. No negative impact on growth and pubertal development was observed.